Key facts
- Calyxo’s last known valuation is $684.6M (Apr 2026).
- It has raised $166.0M across 4 recorded rounds; the latest was Early Stage VC ($40.1M) in Apr 2026.
- Notable investors include Ally Bridge Group, Avidity Partners, CRG, Janus Henderson Investors, Questa Capital — 7 tracked in total.
- Calyxo has filed 4 Form Ds with the SEC since 2022, most recently Apr 2026 ($40.1M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Calyxo
Funding rounds
4 roundsAbout Calyxo
Developer of minimally invasive medical devices designed to improve kidney stone treatment outcomes. The company offers a ureteroscopy-based system with integrated laser lithotripsy for stone fragmentation, continuous irrigation for visualization and procedural control, dynamic aspiration for active removal of stone fragments and debris, and stone collection capabilities to ensure complete extraction, enabling urologists and healthcare providers to achieve stone clearance rates, reduce residual fragments, and improve overall patient outcomes in kidney stone treatment.
- Sector
- Healthcare
- HQ
- Pleasanton, CA, United States
- Founded
- 2016
- Employees
- 321
- Website
- calyxoinc.com/
- Ownership
- Privately Held (backing)
Calyxo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Calyxo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Calyxo in its N-PORT filings yet. We sweep new filings monthly.